[go: up one dir, main page]

WO2013049307A3 - Enhanced immune memory development by aptamer targeted mtor inhibition of t cells - Google Patents

Enhanced immune memory development by aptamer targeted mtor inhibition of t cells Download PDF

Info

Publication number
WO2013049307A3
WO2013049307A3 PCT/US2012/057495 US2012057495W WO2013049307A3 WO 2013049307 A3 WO2013049307 A3 WO 2013049307A3 US 2012057495 W US2012057495 W US 2012057495W WO 2013049307 A3 WO2013049307 A3 WO 2013049307A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
immune memory
enhanced immune
mtor inhibition
memory development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/057495
Other languages
French (fr)
Other versions
WO2013049307A9 (en
WO2013049307A2 (en
Inventor
Eli Gilboa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of WO2013049307A2 publication Critical patent/WO2013049307A2/en
Anticipated expiration legal-status Critical
Publication of WO2013049307A3 publication Critical patent/WO2013049307A3/en
Publication of WO2013049307A9 publication Critical patent/WO2013049307A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure provides compositions for inducing or enhancing immune cell memory. More specifically the compositions provide highly efficient, low toxic and longer lasting protection for treating diseases. The compositions potentiate long-lasting immune memory cells, which are better equipped to provide protective immunity, than the short-lived effector cells generated shortly after vaccination.
PCT/US2012/057495 2011-09-30 2012-09-27 Enhanced immune memory development by aptamer targeted mtor inhibition of t cells Ceased WO2013049307A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541588P 2011-09-30 2011-09-30
US61/541,588 2011-09-30

Publications (3)

Publication Number Publication Date
WO2013049307A2 WO2013049307A2 (en) 2013-04-04
WO2013049307A3 true WO2013049307A3 (en) 2014-04-24
WO2013049307A9 WO2013049307A9 (en) 2014-06-05

Family

ID=47996732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/057495 Ceased WO2013049307A2 (en) 2011-09-30 2012-09-27 Enhanced immune memory development by aptamer targeted mtor inhibition of t cells

Country Status (1)

Country Link
WO (1) WO2013049307A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100116T1 (en) 2014-05-28 2021-05-07 Agenus Inc Anti-gitr antibodies and methods of use thereof
CN105198790B (en) * 2015-04-20 2018-02-16 范国煌 Promote the tetracyclic compound of double negative t cells in-vitro multiplication
TWI716405B (en) 2015-05-07 2021-01-21 美商艾吉納斯公司 Anti-ox40 antibodies and methods of use thereof
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND THEIR METHODS OF USE
AR108038A1 (en) 2016-03-14 2018-07-11 Roche Innovation Ct Copenhagen As OLIGONUCLEOTIDES TO REDUCE THE EXPRESSION OF PD-L1 (PROGRAMMED DEATH LINK-1)
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
CN107974433B (en) * 2017-12-08 2020-12-01 新乡医学院 An enhanced anti-tumor NK cell and its preparation method and application
CN108823211A (en) * 2018-05-04 2018-11-16 中国医学科学院基础医学研究所 A kind of CD19 aptamer and its application
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
CN112807425A (en) * 2021-01-14 2021-05-18 南方医科大学深圳医院 tTIM fusion protein vaccine, preparation method and application
CN120114579A (en) * 2025-04-27 2025-06-10 南京中医药大学 A ginseng cell engineered tumor vaccine and its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240732A1 (en) * 2007-10-01 2010-09-23 University Of Miami Aptamer-targeted sirna to prevent attenuation or suppression of a t cell function
US20110129496A1 (en) * 2008-08-05 2011-06-02 Emory University Use of mTOR Inhibitors to Enhance T Cell Immune Responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240732A1 (en) * 2007-10-01 2010-09-23 University Of Miami Aptamer-targeted sirna to prevent attenuation or suppression of a t cell function
US20110129496A1 (en) * 2008-08-05 2011-06-02 Emory University Use of mTOR Inhibitors to Enhance T Cell Immune Responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PASTOR ET AL.: "Targeting 4-1 BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers.", MOL THER, vol. 19, no. 10, October 2011 (2011-10-01), pages 1878 - 1886, XP008150757, DOI: doi:10.1038/mt.2011.145 *

Also Published As

Publication number Publication date
WO2013049307A9 (en) 2014-06-05
WO2013049307A2 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
WO2013049307A3 (en) Enhanced immune memory development by aptamer targeted mtor inhibition of t cells
WO2012129341A3 (en) Disease detection in plants
EP2544691A4 (en) Compound, composition, and method for protecting skin from high energy visible light
PH12014502445B1 (en) Targeted modification of malate dehydrogenase
WO2012142498A3 (en) Mif inhibitors and their uses
MX2012014904A (en) Methods of treatment using tlr7 and/or tlr9 inhibitors.
EP2655334A4 (en) Compositions and methods useful for treating diseases
IL224390B (en) Compositions and methods for targeted thermomodulation
PL3321355T3 (en) Methods and compositions for the clinical recovery of allogeneic cells, and therapeutic uses
WO2012033814A3 (en) Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
BR112015004327A2 (en) biodegradable compositions, methods and uses thereof
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012054862A9 (en) Agents, compositions, and methods for treating pruritis and related skin conditions
GEP201706668B (en) Parenteral norovirus vaccine formulations
WO2012097185A3 (en) Omv vaccine against burkholderia infections
EP2596017A4 (en) Cross-protective pathogen protection, methods and compositions thereof
EP2586462A4 (en) Prophylactic or ameliorating agent for genetic diseases
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
PL396610A1 (en) Protective grid, especially for protection of slopes
PL2694538T3 (en) Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
WO2009129208A3 (en) Compositions and methods of inducing endoplasmic reticulum stress reponse
WO2011102999A3 (en) Spink1 targeted therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12835212

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12835212

Country of ref document: EP

Kind code of ref document: A2